Skip to main
BDTX

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc is developing silevertinib, a fourth-generation EGFR MasterKey inhibitor, currently undergoing Phase 2 clinical trials for treating EGFR mutant non-small cell lung cancer (NSCLC), which has demonstrated a compelling clinical overall response rate (cORR) of 60%. The company anticipates significant value inflection points from upcoming trial results, particularly for first-line treatment opportunities which are estimated to be in a lucrative market exceeding $1 billion, thus strengthening the perception of silevertinib's efficacy against competitors. Moreover, the favorable outlook for silevertinib is supported by its broad activity across various oncogenic mutations and its demonstrated brain penetration, addressing crucial aspects of treatment for patients with actionable mutations.

Bears say

The analysis of Black Diamond Therapeutics Inc. indicates significant concerns regarding the efficacy and competitive positioning of its lead therapy, silevertinib, in treating patients with EGFR mutant non-small cell lung cancer (NSCLC). The lower clinical overall response rate (cORR) observed in silevertinib compared to competing therapies raises doubts about the drug's ability to gain traction in the market, particularly as high rates of adverse effects have resulted in substantial treatment interruptions and dose reductions. Additionally, the company's current market capitalization of approximately $230 million reflects a lack of investor confidence in silevertinib’s potential for successful outcomes in clinical trials, exacerbating the negative outlook for the stock.

BDTX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 7 analysts, BDTX has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.